| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-807 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1217 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2001-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c84565ecb1da45658e58258a21a58e7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a2519c47094a108717277f5440523a9 |
| publicationDate |
2002-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002197260-A1 |
| titleOfInvention |
Molecular mimetics of unique neisseria meningitidis serogroup B epitopes |
| abstract |
Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004047880-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012054879-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007110632-A1 |
| priorityDate |
1996-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |